Pulmonx Corp. announced its filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the Zephyr® Endobronchial Valve (EBV®), a minimally-invasive and removable device designed to treat severe emphysema, an advanced form of chronic obstructive disease (COPD). The Zephyr EBV is the only device designed for emphysema that hasa clinically-validated diagnostic tool – the Chartis System® – which can identify likely responders in order to optimize patient outcomes. The filing was based on the successful execution of the company’s pivotal IDE trial, the LIBERATE Study, a randomized controlled trial that enrolled 190 patients with severe emphysema at 24 centers in the U.S. and Europe. The trial endpoints at one year included measures of lung function, exercise tolerance and quality of life.